Comparing the effect of magnesium sulfate nebulizer and ipratropium bromide nebulizer in children with asthma
Phase 3
- Conditions
- Magnesium sulfate nebulizer in asthma attack.Severe persistent asthma with (acute) exacerbationJ45.51
- Registration Number
- IRCT20230403057810N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Children with asthma attack
Over 2 years to 18 years
After receiving primary asthma attack treatment (salbutamol)
Stable clinical conditions
Exclusion Criteria
Immunodeficiency
Underlying disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Respiratory rate. Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Lung examination.;Heart rate. Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Cardiac examination.;Blood oxygen saturation percentage. Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Pulse oximetry device.;Wheezing. Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Lung examination with a stethoscope.;Duration of symptoms (less than or more than 6 hours). Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Physical examination.;Treatments after nebulizer administration. Timepoint: After repeated examinations. Method of measurement: General condition of the patient.
- Secondary Outcome Measures
Name Time Method